Enbridge Stock To Go Ex-dividend Tomorrow (ENB)

NEW YORK ( TheStreet) -- The ex-dividend date for Enbridge (NYSE: ENB) is tomorrow, May 11, 2012. Owners of shares as of market close today will be eligible for a dividend of 29 cents per share. At a price of $40.06 as of 9:30 a.m. ET, the dividend yield is 2.9%.

The average volume for Enbridge has been 609,100 shares per day over the past 30 days. Enbridge has a market cap of $31.2 billion and is part of the basic materials sector and energy industry. Shares are up 6.1% year to date as of the close of trading on Wednesday.

Enbridge Inc. engages in the transportation and distribution of crude oil and natural gas primarily in Canada and the United States. The company's Liquids Pipelines segment operates common carrier and contract crude oil, natural gas liquids (NGLs), and refined products pipelines and terminals. The company has a P/E ratio of 31.3, above the average energy industry P/E ratio of 31.2 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Enbridge as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, increase in net income, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had generally poor debt management on most measures that we evaluated. You can view the full Enbridge Ratings Report.

See our dividend calendar or top-yielding stocks list.

null

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)